Skip to content

East-West Collaboration Treatment Using Bee Venom Acupuncture and NSAIDs for Chronic Cervicalgia

Clinical Research on the Efficacy and Safety of East-West Collaborative Treatment Using NSAIDs and BV on Chronic Cervical Pain; A Randomized, Controlled, Parallel, Pilot Study

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01922466
Enrollment
60
Registered
2013-08-14
Start date
2013-07-31
Completion date
2014-07-31
Last updated
2015-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Non-specific, Uncomplicated Neck Pain

Keywords

chronic neck pain, combined treatment between conventional and complementary alternative medical treatment, bee venom acupuncture, NSAIDs

Brief summary

The purpose of this study is to evaluate the efficacy and safety of east-west collaborative treatment using bee venom acupuncture and NSAIDs on pain intensity, functional status and quality of life of patients with chronic cervicalgia

Interventions

PROCEDUREBee Venom Acupuncture

Bee Venom 1:20,000 under BVA Increment Protocol \- Increment Protocol as * 1st week - SC 0.2cc/day, 2 days/week * 2nd week - SC 0.4cc/day, 2 days/week * 3nd week - SC 0.8cc/day, 2 days/week

60 mg/Tab, pers os 1Tab tid, for 3 weeks

Sponsors

Kyung Hee University Hospital at Gangdong
CollaboratorOTHER
Kyunghee University
CollaboratorOTHER
Korea Institute of Oriental Medicine
CollaboratorOTHER_GOV
Kyunghee University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* age between 18 and 65 years * nonspecific, uncomplicated, chronic neck pain over 3 months * volunteer can read and write in Korean, providing written informed consent

Exclusion criteria

* exhibited abnormalities on neurological examination * radicular pain * serious spinal disorders including malignancy, vertebral fracture, spinal infection or inflammatory spondylitis * other chronic diseases that could affect or interfere with the therapeutic outcomes including cardiovascular disease, diabetic neuropathy, active hepatitis, fibromyalgia, rheumatoid arthritis, dementia or epilepsy * previous spinal surgery or scheduled procedures during the study * painful conditions induced by traffic accidents * a substantial musculoskeletal problem generating pain from an area other than the neck * conditions for which administration of BVA might not be safe including clotting disorders, administration of an anticoagulant agent, pregnancy and seizure disorders * a documented hypersensitive reaction to previous BVA treatments, bee stings or insect bites * positive reaction observed during a skin hypersensitivity test * severe psychiatric or psychological disorders * current use of corticosteroids, narcotics, muscle relaxants or herbal medicines to treat neck pain or any medication considered inappropriate by the investigator * pending lawsuits or receipt of compensation due to neck pain.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale for bothersomenessChanges from baseline in VAS at 1st, 2nd, 3rd, 4th and 8th week follow-up

Secondary

MeasureTime frameDescription
Neck Disability IndexChanges from baseline in NDI at 2nd, 3rd, 4th and 8th week follow-up
Depression scores on Beck's Depression InventoryChanges from baseline in BDI at 4th and 8th week follow-up
Quality of Life scores on EQ-5DChanges from baseline in EQ-5D at 2nd, 3rd, 4th and 8th week follow-up
Visual Analogue Scale for pain intensityChanges from baseline in VAS at 1st, 2nd, 3rd, 4th and 8th week follow-up
Safety profileAt every visit, up to 2 monthsAny adverse events must be documented and reported.
Credibility testChanges from baseline in credibility test at 4th week follow-up
Quality of Life scores on SF-36Changes from baseline in SF-36 at 4th and 8th week follow-up

Other

MeasureTime frame
Skin Roll TestChanges from baseline in skinfold thickness and pressure algometer scores at 4th and 8th week follow-up

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026